What they were paid
Kalaris Therapeutics Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $41,250 | $0 | $104,430 | — | $145,680 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Kalaris Therapeutics, Inc. DEF 14A filed April 24, 2026, accession 0001193125-26-177362, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Kalaris Therapeutics pays directors a $40,000 cash retainer and $104,430 in equity.
Committees
FY2025 · as the proxy prints themAudit (Chair)
The rest of the Kalaris Therapeutics board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Andrew Oxtoby | Director | $0 |
| Anthony P. Adamis | Independent Director | $141,905 |
| David Hallal | Chair of the Board | $244,430 |
| Michael Dybbs | Independent Director | $143,430 |
| Morana Jovan-Embiricos | Independent Director | $156,305 |
| Napoleone Ferrara | Independent Director | $151,093 |
| Srinivas Akkaraju | Independent Director | $140,430 |
The full Kalaris Therapeutics compensation record
free company briefThis page is one director within Kalaris Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat